Orum Therapeutics, Inc. (KOSDAQ:475830)

South Korea flag South Korea · Delayed Price · Currency is KRW
85,700
-400 (-0.46%)
Dec 10, 2025, 3:30 PM KST
308.10%
Market Cap1.82T
Revenue (ttm)25.48M
Net Income (ttm)-36.88B
Shares Out21.16M
EPS (ttm)-2,048.17
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume326,096
Average Volume426,785
Open82,300
Previous Close86,100
Day's Range81,100 - 87,100
52-Week Range15,950 - 87,100
Betan/a
RSI74.07
Earnings DateNov 14, 2025

About Orum Therapeutics

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company focuses on degrader-antibody conjugate that combine antibody-drug conjugate with targeted protein degradation technology. Its lead product candidate is ORM-1153, a GSPT1 protein degrader that targets hematologic malignancies. The company was founded in 2016 and is based in Daejeon, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 475830
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.